New York State Common Retirement Fund Has $215,000 Stock Position in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC)

Key Points

• The New York State Common Retirement Fund increased its holdings in Oric Pharmaceuticals by 137.1% in Q1, now owning shares valued at $215,000.
• Insider trading activities included Director Angie You purchasing 26,597 shares at $9.39, while CFO Dominic Piscitelli sold 32,466 shares at an average price of $10.50.
• Wall Street analysts have a consensus buy rating for Oric Pharmaceuticals, with a target price average of $18.57, despite recent fluctuations with shares opening at $11.44.

New York State Common Retirement Fund raised its position in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 137.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,486 shares of the company's stock after buying an additional 22,257 shares during the period. New York State Common Retirement Fund owned 0.05% of Oric Pharmaceuticals worth $215,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Invesco Ltd. raised its stake in shares of Oric Pharmaceuticals by 8.5% in the fourth quarter. Invesco Ltd. now owns 23,958 shares of the company's stock valued at $193,000 after acquiring an additional 1,876 shares during the last quarter. Swiss National Bank increased its holdings in Oric Pharmaceuticals by 5.4% during the 4th quarter. Swiss National Bank now owns 62,400 shares of the company's stock valued at $504,000 after purchasing an additional 3,200 shares in the last quarter. ProShare Advisors LLC raised its position in Oric Pharmaceuticals by 30.9% in the 4th quarter. ProShare Advisors LLC now owns 20,683 shares of the company's stock valued at $167,000 after purchasing an additional 4,881 shares during the last quarter. Geode Capital Management LLC boosted its stake in Oric Pharmaceuticals by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,278,713 shares of the company's stock worth $10,321,000 after purchasing an additional 5,200 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its stake in Oric Pharmaceuticals by 15.3% in the fourth quarter. MetLife Investment Management LLC now owns 41,608 shares of the company's stock worth $336,000 after purchasing an additional 5,530 shares in the last quarter. 95.05% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Angie You acquired 26,597 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The stock was acquired at an average cost of $9.39 per share, with a total value of $249,745.83. Following the completion of the purchase, the director directly owned 26,597 shares in the company, valued at approximately $249,745.83. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Dominic Piscitelli sold 32,466 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $10.50, for a total value of $340,893.00. Following the completion of the sale, the chief financial officer owned 68,317 shares of the company's stock, valued at $717,328.50. This represents a 32.21% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 40,000 shares of company stock worth $416,289. 6.82% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ORIC has been the subject of a number of research reports. Wedbush restated an "outperform" rating and issued a $20.00 target price on shares of Oric Pharmaceuticals in a research note on Monday, June 23rd. Oppenheimer lowered their price objective on shares of Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. LADENBURG THALM/SH SH started coverage on shares of Oric Pharmaceuticals in a research report on Tuesday, July 8th. They set a "buy" rating and a $15.00 target price on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Oric Pharmaceuticals in a research note on Tuesday, May 6th. Finally, HC Wainwright reissued a "buy" rating and issued a $21.00 price target on shares of Oric Pharmaceuticals in a report on Monday, May 5th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $18.57.

Oric Pharmaceuticals Trading Down 2.5%

Shares of NASDAQ ORIC opened at $11.44 on Friday. Oric Pharmaceuticals, Inc. has a 1 year low of $3.90 and a 1 year high of $14.67. The firm's 50-day moving average is $9.46 and its 200-day moving average is $8.08. The firm has a market capitalization of $974.92 million, a PE ratio of -6.12 and a beta of 1.54.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.09. As a group, equities research analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

Want to see what other hedge funds are holding ORIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.